SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2012
Registrant’s telephone number, including area code (858) 222-8041
(Former name or former address, if changed, since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On November 6, 2012, the Board accepted the resignation of Bassam Damaj, Ph.D. as a director, Chief Executive Officer and President of Apricus Biosciences, Inc. and its subsidiaries (the “Company”), effective as of that date. Dr. Damaj’s resignation as a director was made pursuant to a previously tendered conditional resignation provided under the Company’s Corporate Governance Guidelines, which provide that a director who is also an executive officer shall tender a conditional resignation from the Board if they cease to serve as an executive officer of the Company.
Concurrent with Dr. Damaj’s resignation, the Board appointed Steve Martin to serve as the Interim Chief Executive Officer of the Company while the Board conducts a search for a permanent candidate to occupy this position. Mr. Martin is also currently serving as the Company’s Senior Vice President and Chief Financial Officer.
* * *
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.